Roberto Caporali to Italy
This is a "connection" page, showing publications Roberto Caporali has written about Italy.
Connection Strength
0.415
-
COVID-19 related poor mental health and sleep disorders in rheumatic patients: a citizen science project. BMC Psychiatry. 2021 08 03; 21(1):385.
Score: 0.040
-
Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. Ann Rheum Dis. 2021 09; 80(9):1243-1245.
Score: 0.039
-
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. J Rheumatol. 2020 08 01; 47(8):1296.
Score: 0.037
-
What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2021 02; 80(2):e18.
Score: 0.037
-
Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii42-vii53.
Score: 0.033
-
Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus. Biomed Res Int. 2018; 2018:3878953.
Score: 0.033
-
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. Int J Rheum Dis. 2018 Feb; 21(2):422-430.
Score: 0.031
-
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clin Exp Rheumatol. 2017 Jul-Aug; 35(4):660-665.
Score: 0.030
-
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
Score: 0.029
-
Telemedicine in rheumatology: a reliable approach beyond the pandemic. Rheumatology (Oxford). 2021 01 05; 60(1):366-370.
Score: 0.010
-
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 2020 12 30; 22(1):290.
Score: 0.010
-
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun. 2021 01; 116:102545.
Score: 0.009
-
Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis Rheumatol. 2020 10; 72(10):1600-1606.
Score: 0.009
-
COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020 Jul-Aug; 38(4):748-753.
Score: 0.009
-
COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. Semin Arthritis Rheum. 2020 10; 50(5):1150-1157.
Score: 0.009
-
Dealing with COVID-19 in a Pediatric Rheumatology Unit in Italy. Paediatr Drugs. 2020 06; 22(3):263-264.
Score: 0.009
-
Taking care of systemic sclerosis patients during COVID-19 pandemic: rethink the clinical activity. Clin Rheumatol. 2020 Jul; 39(7):2063-2065.
Score: 0.009
-
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. Pediatr Rheumatol Online J. 2020 Apr 22; 18(1):35.
Score: 0.009
-
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmun Rev. 2018 Dec; 17(12):1251-1258.
Score: 0.008
-
Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):804-809.
Score: 0.008
-
Fetal programming and systemic sclerosis. Am J Obstet Gynecol. 2015 Dec; 213(6):839.e1-8.
Score: 0.007